Sales beat changed the fundamental setup
Moderna’s latest read-through is better than the market had been pricing. Reuters reported on November 6, 2026 that the company lifted full-year revenue growth guidance to 15% to 25% after stronger international COVID vaccine demand and partnership payments helped it swing to profit in the third quarter. Reuters also said the FDA cleared Moderna’s flu vaccine, mFlusiva, in August for adults 50 and older, although the company plans only a limited U.S. launch for the 2026-27 flu season because the approval came after flu vaccine contracting. That matters because the market is now being asked to value Moderna less as a single-product COVID story and more as a broader commercial platform, even if execution risk remains high.
Piper Sandler reinforced that shift on November 9, 2026, raising its price target to $305 from $230 and keeping an Overweight rating. The firm cited third-quarter 2026 product sales of $1.27 billion and the improved 2026 revenue guide. Goldman Sachs also turned more constructive on November 12, lifting its target to $195 and noting third-quarter revenue of $1.313 billion versus its own $871 million estimate and market expectations around $890 million. That is a wide spread in target levels, but the direction of revisions is clearly upward after the quarter.
Price action is still lagging the news
MRNA stock is at $219.50, down 0.42% on the day, inside a 24-hour range of $216.32 to $222.85. The stock sits below its 7-day SMA at $230.34 and its 20-day SMA at $234.70, which keeps the short-term trend in distribution. At the same time, the 50-day SMA is $219.15, almost exactly where the shares are trading, so the price is pressing a key pivot rather than breaking cleanly higher or lower.
That leaves the chart in a narrow but important zone. Immediate resistance is $222.79, then $226.09. Immediate support is $216.26, with stronger support at $213.03. The Bollinger middle band is $234.70 and the lower band is $199.68, which means the stock is trading below the midline but still well above the lower envelope. The daily RSI of 45.98 is neutral, while the MACD histogram is flat at 0.0000, so momentum is not confirming a fresh upside break yet. Stochastic readings of 4.38 for %K and 3.51 for %D show the stock is still deeply washed out on the short oscillator, but that alone is not a reversal signal.
Binance perpetual futures lean cautious, not euphoric
On Binance perpetual futures, the funding rate is neutral at 0.0000%, so there is no obvious leverage premium being paid by one side. Open interest is 17,694.87 contracts, with a 24-hour change of -1.26%, which suggests some positioning has come out of the market rather than built into a crowded chase. The global long/short ratio is 0.8751, with Binance global accounts at 46.7% long and 53.3% short as of 2026-11-16 08:00 UTC. Top-trader accounts are similarly skewed short at 52.5% versus 47.5% long.
The more telling line is taker flow: the 1-hour taker buy/sell ratio is 0.3068, with buy volume of 785 against sell volume of 2,558. That points to aggressive selling pressure in the near term. It does not tell you the next direction by itself, but it does say the market is not yet leaning into the post-earnings reset with conviction.
What would change the setup
The key tension is simple: fundamentals improved, but the stock has not yet reclaimed the moving average cluster around the low-$230s. If MRNA can push back above $222.79 and then $226.09, the market can start testing whether the revenue guide upgrade and target revisions deserve a higher trading band. If it loses $216.26, the next obvious risk is a slide toward $213.03, with the Bollinger lower band at $199.68 acting as the deeper technical magnet.
For now, Moderna looks like a stock with better fundamentals than its immediate tape, but not yet a clean trend reversal.



